Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Autolus Therapeutics plc (Nasdaq: AUTL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a commercial-stage biopharmaceutical issuer. Autolus is incorporated in England and Wales, and its American Depositary Shares trade on The Nasdaq Global Select Market. As a foreign private issuer, Autolus files reports and current disclosures with the U.S. Securities and Exchange Commission, including Forms 20-F and 6-K, as well as current reports on Form 8-K related to material events.
In its filings, Autolus provides information on its business of developing, manufacturing and delivering next-generation programmed T cell therapies for cancer and autoimmune disease. Investors can use these documents to follow the commercial launch and performance of AUCATZYL® (obecabtagene autoleucel; obe-cel), a CD19-directed genetically modified autologous T cell immunotherapy indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Filings often reference net product revenue, cost of sales, research and development expenses, and selling, general and administrative expenses, as well as cash, cash equivalents and marketable securities.
Current reports on Form 8-K for Autolus have included quarterly financial results, corporate updates, and governance changes such as the appointment of a principal accounting officer. These documents can also incorporate press releases that discuss clinical trial progress in programs like CATULUS, CARLYSLE, LUMINA, BOBCAT and ALARIC, and provide context on how Autolus is advancing its pipeline across hematological malignancies, solid tumors and autoimmune diseases.
On Stock Titan, SEC filings for AUTL are updated in near real time from EDGAR. Integrated AI-powered summaries help explain the key points in lengthy filings, including annual reports, interim financial updates and material event disclosures. Users can quickly scan for information on Autolus’ T cell programming technologies, AUCATZYL commercialization, manufacturing initiatives and capital position without reading every line of the underlying documents.
Autolus Therapeutics plc’s Chief Business Officer Christopher Michael James Williams filed an initial ownership report, detailing his equity interests in the company. He directly holds 19,808 American Depositary Shares and 8,198 ordinary shares.
He also holds multiple share options over American Depositary Shares with exercise prices ranging from $0.001 to $29.86 per share and expirations extending through 2036. In addition, he has 83,300 restricted share units, which the footnotes state will vest in four equal annual installments beginning on January 26, 2027, each representing the right to receive one American Depositary Share.
Autolus Therapeutics plc Chief Human Resources Officer Alexander Swan filed an initial ownership report detailing his equity in the company. He directly holds 41,343 American Depositary Shares, each convertible into one ordinary share. He also holds several share option grants over additional ADSs with exercise prices ranging from $1.46 to $29.86 and expirations between 2028 and 2036, plus 83,300 restricted share units that vest in four equal annual installments starting on January 26, 2027. The disclosure records existing equity awards and holdings rather than new market purchases or sales.
Autolus Therapeutics plc executive Alex Driggs, SVP Legal Affairs and General Counsel, reports his initial ownership in the company. He directly holds 18,418 American Depositary Shares, plus multiple share options over ADSs with exercise prices ranging from $1.62 to $29.86 expiring between 2028 and 2036, and 33,000 restricted share units that vest in four equal annual installments starting in 2027.
Autolus Therapeutics plc filed an initial ownership report for Chief Technology Officer Neville Miranda Suzette. The filing shows direct ownership of 23,720 American Depositary Shares, each convertible into one ordinary share. Suzette also holds multiple share options to buy ADS at exercise prices between $1.46 and $16.02 expiring from 2030 to 2036, plus 83,300 restricted share units that vest in four equal annual installments starting on January 26, 2027, each RSU representing one ADS.
Autolus Therapeutics plc Schedule 13G/A shows Armistice Capital, LLC and Steven Boyd report beneficial ownership of 17,500,000 American Depositary Shares, representing 6.58% of the class as of November 11, 2025. The filing notes 266,141,286 Shares outstanding as of that date and states Armistice Capital exercises shared voting and dispositive power over those shares as investment manager of Armistice Capital Master Fund Ltd.
Autolus Therapeutics plc received an updated ownership report from MAK Capital and related entities. The group reports beneficial ownership of 30,005,343 American Depositary Shares, representing 11.3% of Autolus’s ordinary shares, based on 266,143,286 ordinary shares outstanding as of November 11, 2025.
The shares are held with shared voting and dispositive power and no sole authority. The reporting parties certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Autolus, indicating a passive investment intent.
Autolus Therapeutics plc filed a prospectus supplement covering the resale by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs), including 3,265,306 ADSs issuable upon exercise of outstanding warrants. The ADSs trade on Nasdaq under the symbol AUTL, and the closing price on January 23, 2026 was $1.46 per ADS.
The supplement also incorporates an 8-K describing a new 10-year Master Supply Agreement between Autolus Limited and AGC Biologics S.p.A for lentiviral vector, a critical raw material for the company’s CAR-T products, including AUCATZYL and clinical trial products. Autolus Limited committed to purchase a minimum of 14 batches of lentiviral vector in the first two calendar years and a minimum value of EUR 25 million of products and services over the subsequent five-year period, under a non-exclusive arrangement that gives AGC a first right to negotiate new manufacturing activities for the obe-cel product.
Autolus Therapeutics plc, through its wholly owned subsidiary Autolus Limited, entered into a 10-year Master Service Agreement with AGC Biologics S.p.A to manufacture and supply lentiviral vector, a key raw material for its CAR-T products for clinical and commercial use. This Agreement replaces the parties’ prior arrangement and sets general terms, with individual projects defined in separate work orders.
The Agreement is non-exclusive and can be terminated for default by either party, or by Autolus on notice subject to certain fees. Autolus has committed to purchase a minimum of 14 batches of lentiviral vector during the first two calendar years of the term, and a minimum value of EUR 25 million in products and services over the subsequent five-year period. AGC also receives a first right to negotiate new manufacturing activities related to Autolus’ obecabtagene autoleucel (obe-cel) product.
Autolus Therapeutics plc reported preliminary, unaudited net product revenue for its CAR-T therapy AUCATZYL (obe-cel). The company expects approximately $24 million of AUCATZYL net product revenue for the fourth quarter of 2025 and approximately $75 million for full year 2025. Based on current operating plans and anticipated AUCATZYL revenues, Autolus believes its cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027.
For 2026, Autolus anticipates AUCATZYL net product revenue in a range of $120 million to $135 million. The company also highlighted updates to its pipeline programs, including development of obe-cel in additional indications such as lupus nephritis and progressive multiple sclerosis, and reiterated plans to expand commercialization and market access, including in Europe. Final 2025 results are expected to be released in March 2026.
Autolus Therapeutics plc is registering 16,645,656 ordinary shares represented by American Depositary Shares (ADSs) on Form S-8 for its equity compensation programs. This includes 3,000,000 ADSs for the 2025 Employee Share Purchase Plan, 3,000,000 ADSs for the 2025 Inducement Plan, and 10,645,656 ADSs for additional awards under the 2018 Equity Incentive Plan following an automatic increase effective October 1, 2025. These ADSs will be used for employee and new-hire equity grants under the company’s existing plans, supplementing amounts previously registered on earlier S-8 filings.